Crizotinib in refractory <scp>ALK</scp>‐positive diffuse large <scp>B</scp>‐cell lymphoma: a case report with a short‐term response

Wass, Maxi; Behlendorf, Timo; Schädlich, Bärbel; Mottok, Anja; Rosenwald, Andreas; Schmoll, Hans‐Joachim; Jordan, Karin

doi:10.1111/ejh.12240

Cited by 33 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of ALK activity resulted in sustained tumour regression in a xenotransplant tumour model. These data indicate a role for CLTC-ALK in the maintenance of the malignant phenotype, which provides a rationale for a therapeutic target for these otherwise refractory tumours [31, 32]. To further study their therapeutic potential in ALK+, LBCL, a CTLC-ALK-positive LBCL cell line (LM1) was established as a preclinical model to study the role of CLTC- ALK activity in DLBCL lymphomagenesis.…”

Section: Discussionmentioning

confidence: 99%

“…In terms of treatment, response to conventional chemotherapy is poor [4]. Due to the limited number of reported cases [5–14], a lack of awareness of this entity, and significant morphologic and immunophenotypic similarities to other haematopoietic and nonhaematopoietic neoplasms, the diagnosis of ALK+, LBCL may be challenging. However, increased awareness of its occurrence and familiarity with its characteristic features are significant for both clinicians and pathologists, particularly with the advancements in emerging therapeutic options [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature

Jiang

Wang

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

We retrospectively analysed 17 cases of anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+, LBCL) according to the morphological, immunohistochemical, molecular and clinical features, using which we intend to elucidate the clinicopathological characteristics of this rare entity. In this study, all cases de facto share common features that defined them as a single entity, and various characteristics may expand the spectrum. Among 15 cases, 60% followed an aggressive clinical course with advanced stage and high IPI scores; the median survival of these patients was only 8 months. An analysis showed that both the IPI score and the Ann Arbor stage were significant prognostic factors. Most patients received a chemotherapy regimen including CHOP, CHOEP, EPOCH, and CVAD, and some also underwent localized radiotherapy. However, ALK+, LBCL cases display a dismal clinical outcome and can only be cured with conventional chemotherapy protocols at the stage of localized disease. Novel front-line intensive chemotherapy regimens should therefore be evaluated in this group of patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature

Jiang

Wang

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Crizotinib, an oral, small-molecule inhibitor of ALK and c-Met, was originally developed as a potential therapeutic agent for ALK-positive anaplastic large cell lymphoma (ALCL) [68] . The drug has indeed demonstrated activity in ALK-positive ALCL [69] as well as ALK-positive diffuse large B cell lymphoma and inflammatory myofibroblastic tumors [70,71] . However, crizotinib has been most widely applied in the treatment of NSCLC with ALK gene rearrangements after marked activity was noted in the patient population in the phase Ⅰ trial, leading to FDA approval of the drug [72] .…”

Section: First-generation Alk Tkimentioning

confidence: 96%

Review of the current targeted therapies for non-small-cell lung cancer

Nguyen

Neal

Wakelee

2014

WJCO

View full text Add to dashboard Cite

The last decade has witnessed the development of oncogene-directed targeted therapies that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this paper we review the data demonstrating efficacy of gefitinib, erlotinib, and afatinib, which target the epidermal growth factor receptor (EGFR), and crizotinib which targets anaplastic lymphoma kinase (ALK). We discuss the challenge of acquired resistance to these small-molecular tyrosine kinase inhibitors and review promising agents which may overcome resistance, including the EGFR T790M-targeted agents CO-1686 and AZD9291, and the ALKtargeted agents ceritinib (LDK378), AP26113, alectinib (CH/RO5424802), and others. Emerging therapies directed against other driver oncogenes in NSCLC including ROS1 , HER2 , and BRAF are covered as well.The identification of specific molecular targets in a significant fraction of NSCLC has led to the personalized deployment of many effective targeted therapies, with more to come. Key words: Lung cancer; Non-small cell lung cancer; Targeted therapies; Epidermal growth factor receptor; Epidermal growth factor receptor; Anaplastic lymphoma kinase; Anaplastic lymphoma kinase; Acquired resistance Core tip: The development of oncogene-directed targeted therapies has significantly changed the treatment of non-small-cell lung cancer. We review the data demonstrating efficacy of small-molecule tyrosine kinase inhibitors against epidermal growth factor receptor, anaplastic lymphoma kinase, ROS1, and other oncogenes. We also discuss the challenge of acquired resistance to these therapies and review promising agents which may overcome resistance.Nguyen KSH, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer.

show abstract

“…Crizotinib, the only ALK inhibitor authorized by the US FDA, has been successfully administered in two refractory ALK+ DLBCL patients and has shown significant antitumor activity. However, these two patients experienced a very short response duration [56,57]. One study evaluated crizotinib in patients with ALK-positive malignances, excluding lung cancer and enrolled ALK+ DLBCL patients, and the results suggested that crizotinib has antitumor activity in advanced ALK-rearranged hematologic tumors; however, further investigation may be warranted in this setting [58].…”

Section: Alk+ Dlbclmentioning

confidence: 99%

CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases

Song

Wang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

CD20 expression is absent in a variety of diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease. These rare and heterogeneous tumors are characterized by the presence of proliferating immunoblasts with similar transcriptional profiles as those of plasma cells and are typically associated with highly aggressive pathologies, with high levels of chemotherapy resistance and low survival rates; thus, they pose significant diagnostic and treatment challenges. We conducted a systematic literature review of the limited existing clinical data to summarize the current knowledge regarding the biological basis, diagnostic limits, and potential therapeutic targets of distinct variants of CD20-negative DLBCL. This review will hopefully increase the awareness of these rare disorders among clinicians and pathologists and prompt basic and clinical research.

show abstract

Crizotinib in refractory ALK‐positive diffuse large B‐cell lymphoma: a case report with a short‐term response

Cited by 33 publications

References 11 publications

Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature

Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature

Review of the current targeted therapies for non-small-cell lung cancer

CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases

Contact Info

Product

Resources

About